01 Expansion of Personalized Phage Therapy The bacteriophages market analysis shows that personalized phage therapy is being developed to match specific bacteriophages with the bacteria causing an individual patient's infection. This approach allows treatment to be selected according to the bacterial strain and its phage sensitivity. This trend strengthens targeted approaches for difficult bacterial infections.
02 Applications of Bacteriophage for Food Safety Bacteriophages are being used to control harmful bacteria such as Listeria and Salmonella in food products and processing environments. These phages can target specific pathogens while having limited effects on other microorganisms. This development expands bacteriophage use in food safety and processing.
01 Supply chain disruptions are expected to have a substantial impact on the bacteriophage market share, as production depends on specialized culture materials, host bacteria, bioreactors, filtration supplies, sterile packaging, and cold chain logistics. The market is likely to follow a capacity-constrained recovery pattern, as phage production requires specialized biological processing and quality-controlled manufacturing capacity that cannot be expanded immediately when supply conditions improve. The market is expected to grow at a CAGR of 5.53%, but supply chain constraints could approximately lower this by 0.4 percentage points, resulting in short-term growth of around 5.13%. As specialized raw materials, bioprocessing capacity, purification supplies, sterile manufacturing, and temperature-controlled logistics stabilize, bacteriophage market growth is expected to gradually return to 5.53%.
01 The bacteriophage market forecasts strategic investment activity driven by phage-based antibotic alternatives, engineered phage therapies, personalized phage cocktails, and applications across human, veterinary, and agricultural health. In October 2025, Phagos raised ~USD 29 million in Series A funding. The capital is intended to accelerate the deployment of veterinary bacteriophage therapies, advance its AI-powered phage-discovery platform, and support expansion across Europe, Asia, and the Americas.
01 Precision Infectious Disease Care and Expanding Biopharmaceutical Research Drives Market Demand The use of targeted approaches in infectious disease treatment is supporting demand for therapies that act against specific bacterial pathogens. The growing role of molecular diagnostics and strain-level pathogen identification allows healthcare providers to evaluate targeted phage therapy alongside other antimicrobial approaches.The expansion of biotechnology research is increasing development activity around bacteriophages for therapeutic, diagnostic, and industrial applications. Investment in phage biomanufacturing and bacteriophage research is supporting the development of scalable platforms for therapeutic phages and other commercial products.
01 Narrow Phage Host Range and Manufacturing Consistency Limit Market Expansion Most bacteriophages target specific bacterial strains rather than a broad range of pathogens. This narrow host range limits their usefulness when the causative bacterial strain is unknown or changes during treatment.Phage products also require controlled production, purification, and characterization to maintain consistent activity. These requirements increase technical complexity in phage biomanufacturing and limit standardized production at a commercial scale.
01 Phage-Based Diagnostics and Development of Engineered Therapeutic Platforms Offer Growth Opportunities to Market Players The development of phage-based diagnostics offers growth opportunities for diagnostic developers, biotechnology companies, and bacteriophage technology providers to create rapid and highly specific bacterial detection platforms. Engineered reporter phages and phage-based biosensors can identify viable bacterial pathogens through specific host recognition and measurable signals, supporting applications in clinical, food-safety, and environmental testing.Bacteriophage engineering also enables developers to design phages with selected biological characteristics for targeted applications. The development of engineered therapeutic platforms offers opportunities for phage manufacturers, biotechnology companies, and synthetic-biology developers to create customized bacteriophages with modified host range, antimicrobial activity, or targeted delivery capabilities.